CD31 and Factor VIII in angiogenesis of normal and pre-eclamptic human placentas

Journal of Obstetrics and Gynaecology

Volumn 32, Issue 6, 2012, Pages 533-536

  Uras, N ^a   Oguz, S S ^a   Zergeroglu, S ^b   Akdag, A ^a   Polat, B ^a   Dizdar, E A ^a   Dilmen, U ^a  

^a Zekai Tahir Burak Maternity and Teaching Hospital   (Turkey)

^b Department of Pathology ^*  (Turkey)

Author keywords

Angiogenesis; CD31; Factor VIII; Pre eclampsia

Indexed keywords

BLOOD CLOTTING FACTOR 8; CD31 ANTIGEN;

ANGIOGENESIS; APGAR SCORE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MICROVASCULATURE; NEWBORN; PLACENTA; PREECLAMPSIA; PRIORITY JOURNAL; SYSTOLIC BLOOD PRESSURE;

ADULT; ANTIGENS, CD31; CASE-CONTROL STUDIES; FACTOR VIII; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; INFANT, NEWBORN; INFANT, SMALL FOR GESTATIONAL AGE; NEOVASCULARIZATION, PHYSIOLOGIC; PLACENTA; PRE-ECLAMPSIA; PREGNANCY; PROSPECTIVE STUDIES; YOUNG ADULT;

EID: 84863744416     PISSN: 01443615     EISSN: 13646893     Source Type: Journal    
DOI: 10.3109/01443615.2012.677875     Document Type: Article

References (20)

1. Ahmad S, Ahmed A. 2004. Elevated placental soluble vascular endothelial growth factor receptor-1 inhibits angiogenesis in preeclampsia. Circulation Research 95:884-891.
2. Brazy JE, Grimm JK, Little VA. 1982. Neonatal manifestations of severe maternal hypertension occurring before the thirty-sixth week of pregnancy. Journal of Pediatrics 100:265-227.
3. Carlstrom M, Wentzel P, Skott O, Persson AE, Eriksson UJ. 2009. Angiogenesis inhibition causes hypertension and placental dysfunction in a rat model of preeclampsia. Journal of Hypertension 27:829-837.
4. Cirpan T, Akercan F, Terek MC, Kazandi M, Ozcakir HT, Giray G et al. 2007. Evaluation of VEGF in placental bed biopsies from preeclamptic women by immunohistochemistry. Clinical and Experimental Obstetrics and Gynecology 34:228-231.
5. Cooper JC, Sharkey AM, Charnock-Jones DS, Palmer CR, Smith SK. 1996. VEGF mRNA levels in placentae from pregnancies complicated by pre-eclampsia. British Journal of Obstetrics and Gynaecology 103:1191-1196.
6. Crowther CA, Bouwmeester AM, Ashurst HM. 1992. Does admission to hospital for bed rest prevent disease progression or improve fetal outcome in pregnancy complicated by non-proteinuric hypertension? British Journal of Obstetrics and Gynaecology 99:13-17.
7. Hsu TY, Lan KC, Tsai CC, Ou CY, Cheng BH, Tsai MY et al. 2009. Expression of androgen receptor in human placentas from normal and preeclamptic pregnancies. Taiwanese Journal of Obstetrics and Gynecology 48:262-267.
8. Levine RJ, Maynard SE, Qian C, Lim KH, England LJ, Yu KF et al. 2004. Circulating angiogenic factors and the risk of preeclampsia. New England Journal of Medicine 350:672-683.
9. Maynard SE, Min JY, Merchan J, Lim KH, Li J, Mondal S et al. 2003. Excess placental soluble Fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. Journal of Clinical Investigation 111:649-658.
10. McKeeman GC, Ardill JE, Caldwell CM, Hunter AJ, McClure N. 2004. Soluble vascular endothelial growth factor receptor-1 (sFlt-1) is increased throughout gestation in patients who have preeclampsia develop. American Journal of Obstetrics and Gynecology 191:1240-1246.
11. Merz R, Said A, Bergstrom S, Bugalho A, Samucidine M. 1992. Pregnancyassociated hypertension in Maputo. A study on maternal characteristics and perinatal outcome in 1275 consecutive cases. International Journal of Gynaecology and Obstetrics 39:11-15.
12. Miettinen M, Lindenmayer AE, Chaubal A. 1994. Endothelial cell markers CD31, CD34, and BNH9 antibody to H- and Y-antigens-evaluation of their specifi city and sensitivity in the diagnosis of vascular tumors and comparison with von Willebrand factor. Modern Pathology 7:82-90.
13. Noris M, Benigni A, Remuzzi G. 1996. Th e role of vasoactive molecules of endothelial origin in the pathophysiology of normal pregnancy and pregnancy-induced hypertension. Current Opinion in Nephrology and Hypertension 5:347-352.
14. Perry KG Jr, Martin JN Jr. 1992. Abnormal hemostasis and coagulopathy in preeclampsia and eclampsia. Clinical Obstetrics and Gynecology 35:338-350.
15. Salahuddin S, Lee Y, Vadnais M, Sachs BP, Karumanchi SA, Lim KH. 2007. Diagnostic utility of soluble Fms-like tyrosine kinase 1 and soluble endoglin in hypertensive diseases of pregnancy. American Journal of Obstetrics and Gynecology 197:28.e1-e6.
16. Sharkey AM, Charnock-Jones DS, Boocock CA, Brown KD, Smith SK. 1993. Expression of mRNA for vascular endothelial growth factor in human placenta. Journal of Reproduction and Fertility 99:609-615.
17. Sibai B, Dekker G, Kupferminc M. 2005. Pre-eclampsia. Lancet 365: 785-799.
18. Tsatsaris V, Goffi n F, Munaut C, Brichant JF, Pignon MR, Noel A et al. 2003. Overexpression of the soluble vascular endothelial growth factor receptor in preeclamptic patients: pathophysiological consequences. Journal of Clinical Endocrinology and Metabolism 88:5555-5563.
19. Venkatesha S, Toporsian M, Lam C, Hanai J, Mammoto T, Kim YM et al. 2006. Soluble endoglin contributes to the pathogenesis of preeclampsia. Nature Medicine 12:642-649.
20. Zhou Y, McMaster M, Woo K, Janatpour M, Perry J, Karpanen T et al. 2002. Vascular endothelial growth factor ligands and receptors that regulate human cytotrophoblast survival are dysregulated in severe preeclampsia and hemolysis, elevated liver enzymes, and low platelets syndrome. American Journal of Pathology 160:1405-1423.